ClinicalTrials.gg
CompletedNCT02617485MADILYMUpdated Oct 25, 2023Results posted

MabionCD20 Compared to MabThera in Lymphoma Patients

A Phase 3 interventional study of Rituximab and Doxorubicin in Diffuse Large B-Cell Lymphoma, sponsored by Mabion SA. Completed at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by Mabion SA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
33rd of 211
143 · median 46
Started
2015
with 5 others
Phase 3
30 of 218
2 open now
Registered
145th of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 33rd largest by enrollment of the 211 interventional ones that give a count, is one of 6 that started in 2015, is one of 30 in phase 3, and was the 145th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20 (MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients with CD20-positive diffuse large B-cell lymphoma.

Read the detailed description

Patients who meet criteria for participation in this study receive 8 intravenous infusions of MabionCD20® or MabThera® 21 days interval in combination with standard dosage regimen of CHOP. The duration of the study is 12 months. The treatment and observation period will last 26 weeks starting from Day 1, until Week 26 - one month after last IMP infusion.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with histological confirmed CD20 (cluster of differentiation 20) positive diffuse large B cell lymphoma (DLBCL)
  2. Patients that had been diagnosed according to the WHO classification;
  3. Performance status ≤ 2 on the (Eastern Cooperative Oncology Group) / WHO (world Health Organization) scale, performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated;

Exclusion criteria

Exclusion Criteria:

  1. Life expectance less than 6 months;
  2. Any chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal therapy for treatment of lymphoma within 28 days prior to treatment;
  3. Rituximab, other anti-CD20 mAb (Monoclonal Antibodies) drug treatment, treatment with any cell depleting therapies - e.g., anti-CD4 (cluster of differentiation 4) anti-CD5 (cluster of differentiation 5), anti-CD3 (cluster of differentiation 3), anti-CD19 (cluster of differentiation 19), anti CD11 (cluster of differentiation 11), anti-CD22 (cluster of differentiation 11), BLys/BAFF (B Lymphocyte Stimulator/B-cell activating factor) within 1,5 years before screening;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    MabionCD20

    A course of MabionCD20 consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles. Intervention: Drug: Rituximab

    Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: prednisone

  • Active comparator
    MabThera

    A course of MabThera consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles. Intervention: Drug: Rituximab

    Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: prednisone

Interventions

  • 375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.

    Also known as: MabThera®, MabionCD20®

  • 50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle

    Also known as: Hydroxydaunorubicin

  • 1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle

    Also known as: Oncovine

  • 750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle

  • 100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])

    Area under the serum concentration-time curve from time zero (Day 1) to final time point measured after the first administration (Week 1) until Week 4 (AUC(W1-W4)). PK blood samples for this endpoint were drawn at Day 1 (before and after the first infusion), Day 8 ± 1 (7 days after first infusion), Day 15 ± 1 (14 days after first infusion), Day 22 ± 2 (before and after completion of the second infusion).

    Time frame: Baseline to Week 4

  2. Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])

    Area under the serum concentration-time curve from time zero to final time point measured from Week 13 until Week 26 (AUC\[W13-W26\]). PK blood samples for this endpoint were drawn at Day 85 ± 4 (before and after completion of the fifth infusion), Day 106 ± 4 (before and after completion of sixth infusion), Day 127 ± 4 (before and after completion of the seventh infusion), Day 148 ± 4 (before and after completion of the eight infusion), Day 155 ± 4 (one week after last infusion) and Day 176 ± 4 (one month after last infusion).

    Time frame: Week 13 to Week 26

Secondary outcomes

  1. Ctrough (Before 8th Infusion)

    Trough serum concentration measured at the end of a dosing interval at steady state, taken directly before eighth infusion.

    Time frame: Week 22

  2. Cmax (Post 5th and 8th Infusion)

    Maximum serum drug concentration (Cmax) at steady state after the 5th and 8th infusions.

    Time frame: Week 13 (5th infusion) and Week 22 (8th infusion)

  3. Kel (Post 5th and 8th Infusions)

    Elimination Rate Constant at steady stade after the 5th and 8th infusions.

    Time frame: Week 13 (5th infusion) and Week 22 (8th infusion)

  4. T1/2 (Post 5th and 8th Infusions)

    Elimination half-life at steady state after the 5th and 8th infusions.

    Time frame: Week 13 to Week 16 and Week 22 to Week 26

  5. CLss (Post 5th and 8th Infusions)

    Clearance at steady state after the 5th and 8th infusions.

    Time frame: Week 13 to Week 16 and Week 22 to Week 26

  6. AUC (W1-W26) B-cell

    Area under the serum concentration-time curve of CD19+ B cell counts, measured from the first administration to the final time point at Week 26 (AUC(1-26) B-cell).

    Time frame: baseline to Week 26

  7. AUC (W1-W26)

    Area under the serum concentration-time curve measured after the first administration (Week 1) until Week 26 (AUC(1-26))

    Time frame: Week 1 until Week 26

  8. Efficacy Assessment at Week 26

    An efficacy assessment was made after 8 treatment cycles (at Week 26) based on tumour responses classified according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (Cheson et al. 1999). Response was assessed based on clinical, radiologic (CT scan) and pathologic (bone marrow) criteria. Possible efficacy responses were: complete response, partial response, stable disease, and progressive disease. Efficacy reported here includes all patients included in the ITT set.

    Time frame: Week 26

  9. Adverse Events

    Percentage of patients with at least one AE in a given category. Data from the entire follow-up are included (Period 1 and Period 2).

    Time frame: from baseline to Week 46

Other outcomes

  1. Immunogenicity

    Percentage of patients with positive ADA or NAb results in a given category. Data pertain to the entire follow-up period (from Baseline to Week 46).

    Time frame: from baseline to Week 46

07

Results

Posted Oct 25, 2023

Participant flow

The trial was initiated in 7 countries (Croatia, Bosnia and Herzegovina, Georgia, Moldova, Poland, Serbia, and Ukraine), but finally only 5 countries with 21 study sites recruited patients (Bosnia and Herzegovina, Georgia, Moldova, Poland, and Ukraine). Start date of recruitment: 29.03.2016

Treatment and Observation Period
Participant flow — Treatment and Observation Period
MilestoneMabionCD20MabThera
Started10040
Completed8535
Not completed155
Withdrew: Adverse event91
Withdrew: Withdrawal by subject41
Withdrew: Patient needed radiotherapy10
Withdrew: Lack of efficacy12
Withdrew: Physician decision01
Follow-up Period
Participant flow — Follow-up Period
MilestoneMabionCD20MabThera
Started8535
Completed7029
Not completed156
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10
Withdrew: Disease progression21
Withdrew: Need for cns prophylaxis10
Withdrew: Patient needed radiotherapy95
Withdrew: Patient needed bone marrow transplantation10

Outcome measures

PrimaryArea Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])

Area under the serum concentration-time curve from time zero (Day 1) to final time point measured after the first administration (Week 1) until Week 4 (AUC(W1-W4)). PK blood samples for this endpoint were drawn at Day 1 (before and after the first infusion), Day 8 ± 1 (7 days after first infusion), Day 15 ± 1 (14 days after first infusion), Day 22 ± 2 (before and after completion of the second infusion).

Time frame:
Baseline to Week 4
Reported as:
Mean · (μg*day)/mL
Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])
(μg*day)/mLMabionCD20MabThera
Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])1559.51 ± 358.0921509.79 ± 382.559
Statistical analysis
  • MabionCD20 vs MabThera · Ratio of geo ls-means: 1.0406 · 90% CI 0.9565 to 1.1321
PrimaryArea Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])

Area under the serum concentration-time curve from time zero to final time point measured from Week 13 until Week 26 (AUC\[W13-W26\]). PK blood samples for this endpoint were drawn at Day 85 ± 4 (before and after completion of the fifth infusion), Day 106 ± 4 (before and after completion of sixth infusion), Day 127 ± 4 (before and after completion of the seventh infusion), Day 148 ± 4 (before and after completion of the eight infusion), Day 155 ± 4 (one week after last infusion) and Day 176 ± 4 (one month after last infusion).

Time frame:
Week 13 to Week 26
Reported as:
Mean · (μg*day)/mL
Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])
(μg*day)/mLMabionCD20MabThera
Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])16498.9 ± 3492.3915647.4 ± 3629.83
Statistical analysis
  • MabionCD20 vs MabThera · Ratio of geo ls-means: 1.0611 · 90% CI 0.9822 to 1.1464
SecondaryCtrough (Before 8th Infusion)

Trough serum concentration measured at the end of a dosing interval at steady state, taken directly before eighth infusion.

Time frame:
Week 22
Reported as:
Mean · μg/mL
Ctrough (Before 8th Infusion)
μg/mLMabionCD20MabThera
Ctrough (Before 8th Infusion)102.246 ± 43.89790.61 ± 41.994
SecondaryCmax (Post 5th and 8th Infusion)

Maximum serum drug concentration (Cmax) at steady state after the 5th and 8th infusions.

Time frame:
Week 13 (5th infusion) and Week 22 (8th infusion)
Reported as:
Mean · μg/mL
Cmax (Post 5th and 8th Infusion)
μg/mLMabionCD20MabThera
5th infusion273.356 ± 65.452266.439 ± 66.086
8th infusion296.784 ± 58.295296.462 ± 69.641
SecondaryKel (Post 5th and 8th Infusions)

Elimination Rate Constant at steady stade after the 5th and 8th infusions.

Time frame:
Week 13 (5th infusion) and Week 22 (8th infusion)
Reported as:
Mean · 1/day
Kel (Post 5th and 8th Infusions)
1/dayMabionCD20MabThera
5th infusion0.05663 ± 0.017940.05418 ± 0.01884
8th infusion0.04335 ± 0.015280.04379 ± 0.0123
SecondaryT1/2 (Post 5th and 8th Infusions)

Elimination half-life at steady state after the 5th and 8th infusions.

Time frame:
Week 13 to Week 16 and Week 22 to Week 26
Reported as:
Mean · days
T1/2 (Post 5th and 8th Infusions)
daysMabionCD20MabThera
5th infusion14.801 ± 12.21815.217 ± 7.889
8th infusion18.301 ± 7.9216.997 ± 4.515
SecondaryCLss (Post 5th and 8th Infusions)

Clearance at steady state after the 5th and 8th infusions.

Time frame:
Week 13 to Week 16 and Week 22 to Week 26
Reported as:
Mean · mL/day
CLss (Post 5th and 8th Infusions)
mL/dayMabionCD20MabThera
5th infusion198.701 ± 53.427206.905 ± 78.213
8th infusion179.168 ± 58.509191.272 ± 89.016
SecondaryAUC (W1-W26) B-cell

Area under the serum concentration-time curve of CD19+ B cell counts, measured from the first administration to the final time point at Week 26 (AUC(1-26) B-cell).

Time frame:
baseline to Week 26
Reported as:
Mean · cells*days/mL blood
AUC (W1-W26) B-cell
cells*days/mL bloodMabionCD20MabThera
AUC (W1-W26) B-cell3395.82 ± 22364.510476.2 ± 56943.0
SecondaryAUC (W1-W26)

Area under the serum concentration-time curve measured after the first administration (Week 1) until Week 26 (AUC(1-26))

Time frame:
Week 1 until Week 26
Reported as:
Mean · (μg*day)/mL
AUC (W1-W26)
(μg*day)/mLMabionCD20MabThera
AUC (W1-W26)28413.6 ± 5194.9826955.3 ± 5849.22
SecondaryEfficacy Assessment at Week 26

An efficacy assessment was made after 8 treatment cycles (at Week 26) based on tumour responses classified according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (Cheson et al. 1999). Response was assessed based on clinical, radiologic (CT scan) and pathologic (bone marrow) criteria. Possible efficacy responses were: complete response, partial response, stable disease, and progressive disease. Efficacy reported here includes all patients included in the ITT set.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Efficacy Assessment at Week 26
ParticipantsMabionCD20MabThera
Complete3414
Partial4218
Stable disease104
Progressive disease102
Missing42
SecondaryAdverse Events

Percentage of patients with at least one AE in a given category. Data from the entire follow-up are included (Period 1 and Period 2).

Time frame:
from baseline to Week 46
Reported as:
Number · percent
Adverse Events
percentMabionCD20MabThera
all AEs71.067.5
TEAEs71.065.0
TESAEs19.012.5
severe TEAEs40.022.5
related TEAEs53.042.5
related severe TEAEs29.022.5
related TESAEs13.05.0
TEAEs leading to death8.00
related TEAEs leading to death2.00
Other pre-specifiedImmunogenicity

Percentage of patients with positive ADA or NAb results in a given category. Data pertain to the entire follow-up period (from Baseline to Week 46).

Time frame:
from baseline to Week 46
Reported as:
Number · participants
Immunogenicity
participantsMabionCD20MabThera
Treatment-induced ADA61
Persistent ADA41
Transient ADA20
Treatment-boosted ADA00
NAb positive00

Adverse events

Collected over 46 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MabionCD208/100 (8%)19/100 (19%)70/100 (70%)
MabThera0/40 (0%)5/40 (12.5%)26/40 (65%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventMabionCD20MabThera
PneumoniaInfections and infestations3/1000/40
Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1000/40
AnaemiaBlood and lymphatic system disorders1/1001/40
Disease progressionGeneral disorders0/1001/40
SepsisInfections and infestations0/1001/40
BronchospasmRespiratory, thoracic and mediastinal disorders0/1001/40
Haemorrhagic strokeNervous system disorders0/1001/40
Cardiac failureCardiac disorders2/1000/40
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/1000/40
HypotensionVascular disorders2/1000/40
Most frequent other events
Showing 10 of 55
Most frequent other events
EventMabionCD20MabThera
NeutropeniaBlood and lymphatic system disorders29/10010/40
LeukopeniaBlood and lymphatic system disorders22/10010/40
AlopeciaSkin and subcutaneous tissue disorders15/1005/40
AnaemiaBlood and lymphatic system disorders14/1005/40
Neutrophil count decreasedInvestigations8/1004/40
White blood count decreasedInvestigations9/1004/40
DiarrhoeaGastrointestinal disorders3/1003/40
Respiratory tract infectionInfections and infestations7/1001/40
StomatitisGastrointestinal disorders3/1002/40
FatigueGeneral disorders5/1001/40

Baseline characteristics

SAF (all patients randomized into the study and receiving at least one infusion of MabionCD20 or MabThera).

Age, Categorical
Age, Categorical(Participants)MabionCD20MabTheraTotal
<=18 years000
Between 18 and 65 years7829107
>=65 years221133
Age, Continuous
Age, Continuous(years)MabionCD20MabTheraTotal
Mean51.5 ± 16.254.3 ± 13.552.3 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)MabionCD20MabTheraTotal
Female542074
Male462066
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MabionCD20MabTheraTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White10040140
More than one race000
Unknown or Not Reported000
BSA
BSA(cubic metre)MabionCD20MabTheraTotal
Mean1.9 ± 0.21.8 ± 0.21.8 ± 0.2
Body weight
Body weight(kilograms)MabionCD20MabTheraTotal
Mean76.2 ± 17.473.6 ± 1775.5 ± 17.2
08

Study locations

35 sites
  • University Clinical Center Banja Luka
    Banja Luka, 78 000, Bosnia and Herzegovina
  • University Clinical Center Sarajevo
    Sarajevo, 71 000, Bosnia and Herzegovina
  • University Clinical Center Tuzla
    Tuzla, 75 000, Bosnia and Herzegovina
  • General Hospital Zenica
    Zenica, 72 000, Bosnia and Herzegovina
  • GH "dr.Josip Bencevic"
    Slavonski Brod, 35000, Croatia
  • CH Merkur
    Zagreb, 10000, Croatia
  • CHC Zagreb
    Zagreb, 10000, Croatia
  • HEMA
    Tbilisi, 0112, Georgia
  • S. Khechinashvili state University clinic
    Tbilisi, 0179, Georgia
  • Medulla - Chemotherapy and Immunotherapy Clinic
    Tbilisi, 0186, Georgia
  • Institut of Oncology, Hematology Department
    Chisinau, 2025, Moldova, Republic of
  • Wojewódzki Szpital Specjalistyczny w Legnicy, Oddział Hematologiczny
    Legnica, 59-220, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr1, Klinika Hematologii i Transplantacji Szpiku
    Lublin, 20-081, Poland
  • Szpital Wojewódzki w Opolu, Oddział Hematologii i Onkologii Hematologicznej
    Opole, 45-061, Poland
  • MTZ Clinical Research Sp. Z o.o.
    Warsaw, 02-106, Poland
  • Clinical Hospital Center Zemun
    Belgrade, 11000, Serbia
  • Clinical Hospital Center Zvezdara
    Belgrade, 11000, Serbia
  • Military Hospital Academy
    Belgrade, 11000, Serbia
  • Public utility "Chernivtsi regional clinical oncology dispensary", Day patient department
    Chernivtsi, 58013, Ukraine
  • Municipal Institution "Dnipropetrovsk City multi-field Clinical Hospital #4", Oncology and medical radiology department
    Dnipropetrovsk, 49102, Ukraine
  • Regional Clinical Hospital of Ivano-Frankivsk, Hematology Department.
    Ivano-Frankivsk, 76008, Ukraine
  • Regional Clinical Oncology Dispensary, Chemotherapy Department
    Ivano-Frankivsk, 76018, Ukraine
  • Kharkiv Regional Clinical Oncology Centre, Deartment of haematology
    Kharkiv, 61070, Ukraine
  • National Institute of Cancer, Department of chemotherapy
    Kiev, 03022, Ukraine
  • Kiev City Clinical Oncological Center, Department of chemotherapy #2
    Kiev, 03115, Ukraine
  • Utility Enterprise "Kirovograd regional oncology dispensary"
    Kirovohrad, 25011, Ukraine
  • Kryvyi Rih Oncology Dispensary, Dnipropetrovsk Highway
    Kryvyi Rih, 50048, Ukraine
  • Volyn' Regional clinical hospital, Haematology Department
    Lutsk, 45634, Ukraine
  • State institution "Institute for haemotopathology and haemotransfusion of National Academy of science of Ukraine
    Lviv, 79044, Ukraine
  • Mykolayiv Region Clinical Hospital, Heamotology department
    Mykolayiv, 54058, Ukraine
  • Poltava regional oncology hospital, heamotherapy department
    Poltava, 36011, Ukraine
  • Regional clinical Hospital named after Novak, Hematology Department
    Uzhgorod, 88000, Ukraine
  • Vinnitsya Regional Clinical Oncology Dispensary, Chemotherapy Department,
    Vinnitsya, 21029, Ukraine
  • Regional Oncology dispensary
    Zaporizhzhia, 69040, Ukraine
  • Zaporizhzhya Regional Clinical Hospital, Deartment of haematology and intensive therapy
    Zaporizhzhia, 69600, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Aug 2017, 20 months.

Results were first posted in Oct 2023, 6 years 2 months after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 20 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2015
First posted
Dec 1, 2015
StartActual
Dec 2015
Primary completionActual
Aug 2017
CompletionActual
Jan 2018
Results first posted
Oct 25, 2023
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02617485
Lead sponsor
Mabion SA
Responsible party
Sponsor
First posted
Dec 1, 2015
Start date
Dec 2015
Primary completion
Aug 2017
Completion
Jan 2018
Results posted
Oct 25, 2023
Last update
Oct 25, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion